Sponsored By
Enter the 2024 Awards!
Join us in celebrating the 11th anniversary of the Global Generics and Biosimilars Awards, a valued recognition of outstanding accomplishments and groundbreaking innovations in the global off-patent pharmaceutical landscape. Held during CPhI Worldwide week in Milan, these prestigious Awards serve as a distinctive platform for industry leaders to convene, engage in insightful discussions about future prospects and challenges, and applaud the exceptional contributions of companies and individuals fostering positive transformations.
Celebrated across 14 distinguished categories, including Biosimilar Initiative of the Year, Leader of the Year, and API Supplier of the Year, we will honor the trailblazers shaping the industry.
Entries for the Global Generics and Biosimilars Awards are open to all at no cost. The thorough judging process will take place throughout the summer, with the announcement of finalists scheduled for September. Witness the unveiling of the winners during the Awards ceremony on Wednesday, 9 October, 2024.
Key details
- Entry Deadline: Monday, 22 July, 2024
- Ceremony: Wednesday, 9 October, 2024
- Free to enter
- Hotel NH Milano Fiera
WHO COULD ENTER
Open to any company which has acquired another company that is active in generics and/or biosimilars, or has acquired a portfolio of generic and/or biosimilar products.
WHAT YOU NEED TO KNOW
Evidence cited in supporting text could include: details of the expected benefits of the acquisition, including anticipated synergies and integration goals as well as strategic or cultural fit. The activities in question should have taken place between 1 September 2023 to 31 July 2024.
WHO COULD ENTER
Open to any company supplying off-patent active pharmaceutical ingredients (APIs) or intermediates.
WHAT YOU NEED TO KNOW
Evidence cited in supporting text could include: details of manufacturing excellence, supply security, customer service, technological achievements or increased efficiencies. The activities in question should have taken place between 1 September 2023 to 31 July 2024.
WHO COULD ENTER
Entries may relate to any biosimilar currently marketed, approved or in clinical development, sales and marketing initiatives, distribution agreements or other initiatives aimed at increasing biosimilar usage.
WHAT YOU NEED TO KNOW
Evidence cited in supporting text could include: strategic advantages, details of overcoming development or technology obstacles, manufacturing efficiency or intellectual property triumphs. The activities in question should have taken place between 1 September 2023 to 31 July 2024.
WHO COULD ENTER
Open to any generics and/or biosimilars alliance, joint venture, distribution agreement, licensing deal or similar that does not involve the acquisition of another company or a portfolio of products.
WHAT YOU NEED TO KNOW
Evidence cited in supporting text could include: details of the expected benefits of the business development activities, including anticipated financial or strategic advantages. The activities in question should have taken place between 1 September 2023 to 31 July 2024.
WHO COULD ENTER
This category allows industry firms and organizations to highlight outstanding campaigns used to successfully promote and highlight generics, biosimilars and value-added medicines across the world. This could include awareness campaigns, efforts to highlight key industry contributions to a wider audience, or initiatives that raise the profile of off-patent medicines for healthcare industry stakeholders.
WHAT YOU NEED TO KNOW
Evidence cited in supporting text could include: industry thought leadership, outreach achieved, social media and media interest or collaboration with regulatory authorities. The activities in question should have taken place between 1 September 2023 to 31 July 2024.
WHO COULD ENTER
Open to any company that generates at least a third, or at least US $250 million, of its annual sales from generics or biosimilars.
WHAT YOU NEED TO KNOW
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. The activities in question should have taken place between 1 September 2023 to 31 July 2024.
WHO COULD ENTER
Open to any company that generates at least a third, or at least US$250 million, of its annual sales from generics and biosimilars. Qualification for a region is dependent on the headquarters (not tax domicile) of a company’s generics and/or biosimilars business.
- Company of the Year — Americas | sponsored by
- Company of the Year — Asia-Pacific
- Company of the Year — EMEA
WHAT YOU NEED TO KNOW
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. The activities in question should have taken place between 1 September 2023 to 31 July 2024.
WHO COULD ENTER
Humanitarian charity International Health Partners (IHP) has partnered with Generics Bulletin to create this Award. Entries could include: company approach to CSR, implementation, engagement plans, raining & education programmes, compulsory licensing and humanitarian aid donations.
WHAT YOU NEED TO KNOW
Evidence cited in supporting text could include: details of the positive impact of CSR activities, innovative or original approaches to CSR, or positive corporate cultural changes. The activities in question should have taken place between 1 September 2023 to 31 July 2024.
WHO COULD ENTER
Awarded to recognize outstanding achievements by firms or individuals that work alongside generics and biosimilars manufacturers and suppliers. These could include logistics providers, contract-research organisations, contract-manufacturers, law firms and consultants.
WHAT YOU NEED TO KNOW
Evidence cited in supporting text could include: details of outstanding collaborations with generics, biosimilars or value-added medicines suppliers, customer service, or innovations benefiting the off-patent industry. The activities in question should have taken place between 1 September 2023 to 31 July 2024.
WHO COULD ENTER
Open to any member of the senior management team of a firm within the generics or biosimilars industries. Judges will want to see how the entered leaders have best applied company values within the business environment – achieving measured and sustainable growth, driving improved performance, delivering shareholder value, implementing robust strategies, engaging staff, demonstrating market knowledge and true customer insight.
WHAT YOU NEED TO KNOW
Evidence cited in supporting text could include: evidence of successful strategies or initiatives implemented, executive team management, industry-level leadership or positive effects on company culture. The activities in question should have taken place between 1 September 2023 to 31 July 2024.
WHO COULD ENTER
Awarded to identify excellence in the regulatory sphere. This could include innovative approaches to obtaining marketing authorisations, regulatory milestones for individual companies, or developments that represent a wider breakthrough for the global generics and/or biosimilars industries.
WHAT YOU NEED TO KNOW
Evidence cited in supporting text could include: details of overcoming development or technology obstacles, competitive advantages, regulatory efficiency or benefits to patient populations. The activities in question should have taken place between 1 September 2023 to 31 July 2024.
WHO COULD ENTER
Entries in this category could include known molecules that are repurposed for new indications, reformulated in a way that adds value for patients, put together in innovative combinations, or which feature added-value packaging or delivery methods.
WHAT YOU NEED TO KNOW
Evidence cited in supporting text could include: innovation, addressing unmet needs, overcoming regulatory or technology obstacles, intellectual property triumphs or marketing success. The activities in question should have taken place between 1 September 2023 to 31 July 2024.
HEADLINE SPONSOR
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. IQVIA creates intelligent connections to deliver powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 86,000 employees, IQVIA conducts operations in more than 100 countries. Learn more at www.iqvia.com.
The research side of our business is currently being built up, starting from the base of our well-regarded industry blog. Look out for the first in our series of in-depth reports beginning in 2015.
Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.
The Biosimilars Council is a division of the Association for Accessible Medicines, an organization dedicated to improving access to safe, quality, effective medicine. To learn more, visit www.accessiblemeds.org
